Georgios Tsivgoulis1, Nitin Goyal1, Ali Kerro1, Aristeidis H Katsanos1, Rashi Krishnan1, Konark Malhotra1, Abhi Pandhi1, Peter Duden1, Aman Deep1, Reza Bavarsad Shahripour1, Tomas Bryndziar1, Katherine Nearing1, Boris Chulpayev1, Jason Chang1, Ramin Zand1, Anne W Alexandrov1, Andrei V Alexandrov2. 1. From the Department of Neurology (G.T., N.G., A.K., R.K., A.P., P.D., A.D., R.B.S., T.B., K.N., B.C., J.C., R.Z., A.W.A., A.V.A.), University of Tennessee Health Science Center, Memphis; Second Department of Neurology (G.T., A.H.K.), Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece; Department of Neurology (K.M.), West Virginia University-Charleston Division; Department of Critical Care Medicine (J.C.), MedStar Washington Hospital Center, Washington, DC; and Department of Neurology (R.Z.), Geisinger Health System, Danville, PA. 2. From the Department of Neurology (G.T., N.G., A.K., R.K., A.P., P.D., A.D., R.B.S., T.B., K.N., B.C., J.C., R.Z., A.W.A., A.V.A.), University of Tennessee Health Science Center, Memphis; Second Department of Neurology (G.T., A.H.K.), Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece; Department of Neurology (K.M.), West Virginia University-Charleston Division; Department of Critical Care Medicine (J.C.), MedStar Washington Hospital Center, Washington, DC; and Department of Neurology (R.Z.), Geisinger Health System, Danville, PA. avalexandrov@att.net.
Abstract
OBJECTIVE: We sought to determine the safety and efficacy of IV thrombolysis (IVT) in acute ischemic stroke (AIS) patients with a history of dual antiplatelet therapy pretreatment (DAPP) in a prospective multicenter study. METHODS: We compared the following outcomes between DAPP+ and DAPP- IVT-treated patients before and after propensity score matching (PSM): symptomatic intracranial hemorrhage (sICH), asymptomatic intracranial hemorrhage, favorable functional outcome (modified Rankin Scale score 0-1), and 3-month mortality. RESULTS: Among 790 IVT patients, 58 (7%) were on DAPP before stroke (mean age 68 ± 13 years; 57% men; median NIH Stroke Scale score 8). DAPP+ patients were older with more risk factors compared to DAPP- patients. The rates of sICH were similar between groups (3.4% vs 3.2%). In multivariable analyses adjusting for potential confounders, DAPP was associated with higher odds of asymptomatic intracranial hemorrhage (odds ratio = 3.53, 95% confidence interval: 1.47-8.47; p = 0.005) but also with a higher likelihood of 3-month favorable functional outcome (odds ratio = 2.41, 95% confidence interval: 1.06-5.46; p = 0.035). After propensity score matching, 41 DAPP+ patients were matched to 82 DAPP- patients. The 2 groups did not differ in any of the baseline characteristics or safety and efficacy outcomes. CONCLUSIONS: DAPP is not associated with higher rates of sICH and 3-month mortality following IVT. DAPP should not be used as a reason to withhold IVT in otherwise eligible AIS candidates. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for IVT-treated patients with AIS, DAPP is not associated with a significantly higher risk of sICH. The study lacked the precision to exclude a potentially meaningful increase in sICH bleeding risk.
OBJECTIVE: We sought to determine the safety and efficacy of IV thrombolysis (IVT) in acute ischemic stroke (AIS) patients with a history of dual antiplatelet therapy pretreatment (DAPP) in a prospective multicenter study. METHODS: We compared the following outcomes between DAPP+ and DAPP- IVT-treated patients before and after propensity score matching (PSM): symptomatic intracranial hemorrhage (sICH), asymptomatic intracranial hemorrhage, favorable functional outcome (modified Rankin Scale score 0-1), and 3-month mortality. RESULTS: Among 790 IVT patients, 58 (7%) were on DAPP before stroke (mean age 68 ± 13 years; 57% men; median NIH Stroke Scale score 8). DAPP+patients were older with more risk factors compared to DAPP- patients. The rates of sICH were similar between groups (3.4% vs 3.2%). In multivariable analyses adjusting for potential confounders, DAPP was associated with higher odds of asymptomatic intracranial hemorrhage (odds ratio = 3.53, 95% confidence interval: 1.47-8.47; p = 0.005) but also with a higher likelihood of 3-month favorable functional outcome (odds ratio = 2.41, 95% confidence interval: 1.06-5.46; p = 0.035). After propensity score matching, 41 DAPP+patients were matched to 82 DAPP- patients. The 2 groups did not differ in any of the baseline characteristics or safety and efficacy outcomes. CONCLUSIONS:DAPP is not associated with higher rates of sICH and 3-month mortality following IVT. DAPP should not be used as a reason to withhold IVT in otherwise eligible AIS candidates. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for IVT-treated patients with AIS, DAPP is not associated with a significantly higher risk of sICH. The study lacked the precision to exclude a potentially meaningful increase in sICH bleeding risk.
Authors: Eivind Berge; William Whiteley; Heinrich Audebert; Gian Marco De Marchis; Ana Catarina Fonseca; Chiara Padiglioni; Natalia Pérez de la Ossa; Daniel Strbian; Georgios Tsivgoulis; Guillaume Turc Journal: Eur Stroke J Date: 2021-02-19
Authors: Brett A Eyford; Chaahat S B Singh; Thomas Abraham; Lonna Munro; Kyung Bok Choi; Tracy Hill; Rhonda Hildebrandt; Ian Welch; Timothy Z Vitalis; Reinhard Gabathuler; Jacob A Gordon; Hans Adomat; Emma S T Guns; Chieh-Ju Lu; Cheryl G Pfeifer; Mei Mei Tian; Wilfred A Jefferies Journal: Front Mol Biosci Date: 2021-03-26
Authors: Yan Zhang; Jianliang Wang; Zhaoxi Ma; Guihua Mu; Da Liang; Yifan Li; Xiaoyan Qian; Luyuan Zhang; Fang Shen; Lei Zhang; Jie Yu; Yang Liu Journal: Front Neurol Date: 2022-10-04 Impact factor: 4.086